BiO2 Medical catches $12m to market emboli filter
This article was originally published in Clinica
Executive Summary
BiO2 Medical has raised $12 million in Series C funding which will enable the San Antonio, Texas firm to commercialise its Angel pulmonary embolism prevention device. The round was led by new investor Remeditex Ventures, with participation from BiO2's existing investors.